Settlement Agreements, Prestigious Recognitions, Proposed M&A's, and Support
for New Drug Candidates - Research Report on Teva, Aegerion, Community Health
Systems, Air Methods and Vanda
Editor Note: For more information about this release, please scroll to bottom.
NEW YORK, November 28, 2013
NEW YORK, November 28, 2013 /PRNewswire/ --
Today, Analysts' Corner announced new research reports highlighting Teva
Pharmaceutical Industries Limited (NYSE: TEVA), Aegerion Pharmaceuticals, Inc.
(NASDAQ: AEGR), Community Health Systems, Inc. (NYSE: CYH), Air Methods Corp.
(NASDAQ: AIRM) and Vanda Pharmaceuticals Inc. (NASDAQ: VNDA). Today's readers
may access these reports free of charge - including full price targets,
industry analysis and analyst ratings - via the links below.
Teva Pharmaceutical Industries Limited Research Report
On November 25, 2013, Teva Pharmaceuticals Industries Limited (Teva
Pharmaceuticals) and Mylan Inc. jointly announced that certain of its
affiliates have come to a settlement agreement and dismiss the pending patent
litigation involving Copaxone in the United Kingdom, the Netherlands and
France relating to non-infringement and the validity of European Patent
0,762,888, which expires in May 2015. The companies did not disclose the terms
of the settlement. The Full Research Report on Teva Pharmaceutical Industries
Limited - including full detailed breakdown, analyst ratings and price targets
- is available to download free of charge at:
Aegerion Pharmaceuticals, Inc. Research Report
On November 18, 2013, Aegerion Pharmaceuticals, Inc. (Aegerion) announced that
it has been named as one of the Top Places to Work in Boston in 2013 by the
Boston Globe. The Company ranked 20th out of 115 in the small employer
category (defined as companies with 50-99 Massachusetts-based employees).
"Aegerion has experienced significant growth in the past year, and one of our
top priorities is to maintain our employee-focused culture," said Marc D.
Beer, CEO of Aegerion. "Having Aegerion employees elect the Company as a Top
Place to Work is a source of great pride for our organization. This honor is a
reflection of our dedicated employees who pursue our mission to treat patients
with rare diseases." The Full Research Report on Aegerion Pharmaceuticals,
Inc. - including full detailed breakdown, analyst ratings and price targets -
is available to download free of charge at:
Community Health Systems, Inc. Research Report
On November 22, 2013, Community Health Systems, Inc. (CHS) and Health
Management Associates, Inc. (HMA) announced that the Registration Statement on
Form S-4 relating to the companies' proposed merger has been declared
effective by the Securities and Exchange Commission (SEC). "We are pleased
that the SEC has completed its review, and we can continue to move towards the
successful completion of our acquisition of HMA," said Wayne T. Smith,
Chairman, President and CEO of CHS. "We continue to believe this transaction
represents full and fair value for HMA stockholders, while positioning CHS for
long-term growth that will generate incremental stockholder value and benefit
local communities and patients around the country." The transaction is
expected to be completed during Q1 2014 and is subject to approval of HMA
stockholders holding 70% of HMA's outstanding shares, antitrust clearance,
receipt of other regulatory approvals, and the absence of certain adverse
developments. The Full Research Report on Community Health Systems, Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
Air Methods Corp. Research Report
On November 18, 2013, Air Methods Corp. (Air Methods) announced that it has
entered into a definitive agreement to acquire Blue Hawaiian Helicopters and
its affiliates (Blue Hawaiian), a helicopter tour operator based in Hawaii.
Commenting on the acquisition agreement, Aaron Todd, Air Methods' CEO, stated
"the acquisition of Blue Hawaiian, when combined with Sundance Helicopters,
our aerial tour operator acquired in December 2012, will position Air Methods
Tours as the leading aerial tour provider in two of the most coveted tourism
venues in the United States: the Las Vegas/Grand Canyon region and Hawaii."
The transaction is expected to close in Q4 2013. The Full Research Report on
Air Methods Corp. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:
Vanda Pharmaceuticals Inc. Research Report
On November 15, 2013, Bloomberg reported that Vanda Pharmaceuticals Inc.
(Vanda) has won the backing of U.S. advisers for an experimental drug known as
tasimelteon, to regulate the circadian rhythms of blind people to help them
sleep. According to the report, Food and Drug Administration said that Vanda's
medicine is effective and safe for use. Further, Bloomberg stated that the
medication, which the Company has proposed calling Hetlioz, is supposed to
help synchronize the body with a 24-hour cycle. No other approved treatments
exist for the condition called non-24-hour disorder, which affects about
80,000 totally blind people in the U.S., the report added. The FDA is expected
to decide on whether to approve Vanda's drug by January 31, 2013. The Full
Research Report on Vanda Pharmaceuticals Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at:
1.This is not company news. We are an independent source and our views do
not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
only human and are prone to make mistakes. If you notice any errors or
omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
increase awareness for mentioned companies to our subscriber base and the
4.If you wish to have your company covered in more detail by our team, or
wish to learn more about our services, please contact us at
5.For any urgent concerns or inquiries, please contact us at
6.Are you a public company? Would you like to see similar coverage on your
company? Send us a full investors' package to
research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
SOURCE Analysts' Corner
Contact: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North America)
Press spacebar to pause and continue. Press esc to stop.